

AMENDMENTS TO THE SPECIFICATION:

Please amend the specification as follows:

Page 8, lines 16-19, please amend the paragraph as follows:

Antidiabetics include insulin and insulin derivatives, such as, for example, Lantus® or HMR 1964, GLP-1 derivatives, such as, for example, those disclosed by Novo Nordisk A/S in ~~WO 98/08874~~ U.S. Patent No. 6,268,343, the disclosure of which is incorporated by reference herein, and oral hypoglycemic active compounds.

Page 8, line 21 to page 9, line 1, please amend the paragraph as follows:

The oral hypoglycemic active compounds preferably include sulfonyl ureas, biguadines, meglitinides, oxadiazolidinediones, thiazolidinediones, glucosidase inhibitors, glucagon antagonists, GLP-1 agonists, potassium channel openers, such as, for example, those disclosed by Novo Nordisk A/S in ~~WO 97/26265~~ U.S. Patent No. 5,889,002 and ~~WO 99/03861~~ U.S. Patent No. 6,225,310, the disclosures of which are incorporated by reference herein, insulin sensitizers, inhibitors of liver enzymes involved in stimulating gluconeogenesis and/or glycogenolysis, modulators of glucose uptake, compounds which modulate lipid metabolism, such as antihyperlipidemic active compounds and antilipidemic active compounds, compounds which reduce food intake, PPAR and PXR agonists and active compounds which act on the ATP-dependent potassium channel of the beta cells.